Stockhub

Nordic Nanovector ASA: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

23 September 2022

  • curprev 06:5606:56, 23 September 2022 95.149.241.133 talk 1,076 bytes +1,076 Created page with "== Summary<ref>Source: Yahoo Finance.</ref> == Nordic Nanovector ASA, a biopharmaceutical company, develops and commercializes therapeutics for hematological cancers in Norway. The company's lead product candidate is Betalutin, a CD37-targeting antibody-radionuclide-conjugate, which is in Phase 2b clinical trial for the treatment of patients with non-hodgkin lymphoma. Its preclinical development product also includes Alpha37, an anti-CD37 alphaparticle emitting radioimm..."
Retrieved from "https://stockhub.co/research/Nordic_Nanovector_ASA"